Compare PTY & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PTY | DAWN |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | 2002 | 2021 |
| Metric | PTY | DAWN |
|---|---|---|
| Price | $12.25 | $21.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $24.43 |
| AVG Volume (30 Days) | 1.1M | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $158,182,000.00 |
| Revenue This Year | N/A | $55.03 |
| Revenue Next Year | N/A | $28.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 20.60 |
| 52 Week Low | $11.58 | $5.64 |
| 52 Week High | $14.69 | $21.53 |
| Indicator | PTY | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 54.17 | 80.29 |
| Support Level | $11.97 | $10.30 |
| Resistance Level | $12.36 | N/A |
| Average True Range (ATR) | 0.10 | 0.03 |
| MACD | 0.03 | -0.28 |
| Stochastic Oscillator | 71.79 | 90.91 |
PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on a public or private basis.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.